ChemGenex and MolecularMD team up in drug resistance deal
ChemGenex has teamed up with MolecularMD in a deal that focuses on a drug resistance mutation seen in chronic myeloid leukemia (CML) patients, which has seen these sufferers no longer respond to Gleevec, a popular cancer treatment.